Study outcomes for patients treated with blinatumomab. At 1 year, the rate of relapse was 29% (95% CI, 11%-49%) (A), progression-free survival (PFS) 71% (95% CI, 47%-86%) (B), and overall survival (OS) 85% (95% CI, 61%-95%) (C).